EP4678174A1 — Nizubaglustat for use in the treatment of lysosomal storage disorders
Assigned to Azafaros BV · Expires 2026-01-14 · 0y expired
What this patent protects
The invention relates to nizubaglustat for use in the treatment of a lysosomal storage disorder in a human subject. Specifically, the invention relates to the administration of nizubaglustat at a dose of 3mg - 9mg total/day.
USPTO Abstract
The invention relates to nizubaglustat for use in the treatment of a lysosomal storage disorder in a human subject. Specifically, the invention relates to the administration of nizubaglustat at a dose of 3mg - 9mg total/day.
Drugs covered by this patent
- Ztalmy (GANAXOLONE) · Marinus
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.